MRK

NYSE · Pharmaceuticals

Merck & Co. Inc.

S&P 500 Dow Jones Mega-Cap Stocks Blue Chip Stocks Pharmaceutical Stocks Healthcare Stocks Best Dividend Stocks

$128.63

+0.30 (+0.23%)

As of Aug 6, 9:30 PM ET ·

Financial Highlights (FY 2026)

Revenue

64.31B

Net Income

18.06B

Gross Margin

77.1%

Profit Margin

28.1%

Rev Growth

+3.1%

D/E Ratio

0.94

Revenue & Net Income

Margin Trends

	FY 2026	FY 2025	FY 2024	FY 2023
Gross Margin	77.1%	77.1%	60.0%	60.0%
Operating Margin	32.6%	29.4%	19.9%	18.6%
Profit Margin	28.1%	26.7%	14.5%	15.3%

Income Statement

	FY 2026	FY 2025	FY 2024	FY 2023
Revenue	64.31B	62.37B	122.92B	97.21B
Gross Profit	49.57B	48.07B	73.70B	58.29B
Operating Income	20.99B	18.32B	24.40B	18.09B
Net Income	18.06B	15.76B	17.77B	14.84B
Gross Margin	77.1%	77.1%	60.0%	60.0%
Operating Margin	32.6%	29.4%	19.9%	18.6%
Profit Margin	28.1%	26.7%	14.5%	15.3%
Rev Growth	+3.1%	+3.1%	+3.7%	+0.8%

Balance Sheet

	FY 2026	FY 2025	FY 2024	FY 2023
Total Debt	78.14B	78.14B	126.52B	165.60B
Total Equity	83.31B	83.31B	163.18B	146.99B
D/E Ratio	0.94	0.94	0.78	1.13

Cash Flow

	FY 2026	FY 2025	FY 2024	FY 2023
EBITDA	24.00B	22.11B	40.31B	27.40B
Free Cash Flow	—	—	15.03B	9.18B